The Manufacturers Life Insurance Company Buys Shares of 62,829 Dianthus Therapeutics, Inc. $DNTH

The Manufacturers Life Insurance Company bought a new position in Dianthus Therapeutics, Inc. (NASDAQ:DNTH) during the 2nd quarter, HoldingsChannel.com reports. The fund bought 62,829 shares of the company’s stock, valued at approximately $6,125,000.

A number of other hedge funds and other institutional investors also recently made changes to their positions in DNTH. Spruce Street Capital LP purchased a new stake in shares of Dianthus Therapeutics during the 2nd quarter worth about $34,587,464. Elevation Point Wealth Partners LLC acquired a new position in Dianthus Therapeutics in the second quarter worth approximately $868,000. Quantbot Technologies LP acquired a new position in Dianthus Therapeutics in the second quarter worth approximately $174,000. Emerald Investment Advisers LLC bought a new position in Dianthus Therapeutics during the second quarter valued at approximately $2,579,000. Finally, E Fund Management Co. Ltd. bought a new position in Dianthus Therapeutics during the second quarter valued at approximately $497,000. 47.53% of the stock is owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

A number of analysts have issued reports on the stock. Wall Street Zen upgraded shares of Dianthus Therapeutics from a “sell” rating to a “hold” rating in a research note on Saturday, May 9th. Raymond James Financial restated a “strong-buy” rating and set a $131.00 price target on shares of Dianthus Therapeutics in a report on Wednesday, August 5th. HC Wainwright lifted their price objective on shares of Dianthus Therapeutics from $130.00 to $158.00 and gave the company a “buy” rating in a research note on Thursday, August 6th. Wolfe Research reiterated an “outperform” rating on shares of Dianthus Therapeutics in a report on Wednesday, June 10th. Finally, Truist Financial upped their price objective on shares of Dianthus Therapeutics from $110.00 to $128.00 and gave the stock a “buy” rating in a report on Thursday, August 6th. One analyst has rated the stock with a Strong Buy rating, twelve have given a Buy rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $124.27.

Insider Activity at Dianthus Therapeutics

In other Dianthus Therapeutics news, Director Simon Read sold 2,778 shares of the business’s stock in a transaction on Wednesday, August 19th. The shares were sold at an average price of $117.55, for a total value of $326,553.90. Following the sale, the director owned 2,778 shares of the company’s stock, valued at $326,553.90. The trade was a 50.00% decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through this link. Also, CEO Marino Garcia sold 166,000 shares of the company’s stock in a transaction that occurred on Friday, August 7th. The shares were sold at an average price of $108.11, for a total value of $17,946,260.00. Following the completion of the sale, the chief executive officer owned 65,292 shares in the company, valued at approximately $7,058,718.12. This represents a 71.77% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold 260,554 shares of company stock worth $27,211,775 in the last three months. Company insiders own 3.02% of the company’s stock.

Dianthus Therapeutics Price Performance

NASDAQ DNTH opened at $105.61 on Tuesday. The company’s fifty day moving average is $103.96 and its two-hundred day moving average is $87.71. Dianthus Therapeutics, Inc. has a 52-week low of $22.81 and a 52-week high of $117.88. The firm has a market capitalization of $5.77 billion, a price-to-earnings ratio of -25.45 and a beta of 1.22.

Dianthus Therapeutics (NASDAQ:DNTH) last announced its quarterly earnings data on Tuesday, August 4th. The company reported ($0.90) EPS for the quarter, missing analysts’ consensus estimates of ($0.85) by ($0.05). Dianthus Therapeutics had a negative net margin of 10,096.95% and a negative return on equity of 22.53%. The company had revenue of $0.76 million for the quarter, compared to analyst estimates of $0.30 million. As a group, sell-side analysts expect that Dianthus Therapeutics, Inc. will post -3.83 earnings per share for the current fiscal year.

About Dianthus Therapeutics

Dianthus Therapeutics, Inc, a clinical-stage biotechnology company, develops complement therapeutics for patients with severe autoimmune and inflammatory diseases. It is developing DNTH103, a monoclonal antibody, which is in Phase 2 clinical trial, for the treatment of generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy. Dianthus Therapeutics, Inc was founded in 2019 and is headquartered in New York, New York.